Logo

Asieris Signs a Worldwide Development and Commercialization Agreement with Photocure for Cevira

Share this

Asieris Signs a Worldwide Development and Commercialization Agreement with Photocure for Cevira

Shots:

  • Photocure to receive $5M upfront within 6mos. after signing the agreement and $14M on the approval of the second indication in the US- China & EU with royalties on sales. Photocure will also receive $18M & $36M as a regulatory & clinical milestone in China & the US and EU respectively
  • The companies collaborated to develop & commercialize Cevira for the treatment of HPV induced cervical precancerous lesions. Asieris will be responsible for the manufacturing of the Cevira and Photocure will responsible for the manufacturing of API
  • Cevira is photo-dynamic drug-device combination therapy- being developed for non-surgical treatment of cervical dysplasia- placed on the cervix by the gynecologist with no disruption in normal activities

Click here to read full press release/ article | Ref: PRNewsWire | Image: Photocure


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions